Kristin Stephens - Jun 8, 2021 Form 3 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Development Officer
Signature
/s/ Kristin Stephens
Stock symbol
SYRS
Transactions as of
Jun 8, 2021
Transactions value $
$0
Form type
3
Date filed
6/10/2021, 05:23 PM
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SYRS Common Stock 45K Jun 8, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 20K $6.94 Direct F2
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 6.67K $8.51 Direct F2
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 6.67K $11.66 Direct F2
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 12.8K $12.59 Direct F2
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 38.2K $10.90 Direct F2
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 30K $10.09 Direct F3
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 7.2K $12.29 Direct F4
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 53.4K $6.71 Direct F5
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 84K $7.54 Direct F6
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 10K $9.17 Direct F7
holding SYRS Stock Option (right to buy) Jun 8, 2021 Common Stock 94K $11.41 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022.
F2 This option is fully vested.
F3 Option vested as to 25% of the shares on February 28, 2019 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2022.
F4 Option vested as to 25% of the shares on August 31, 2019 with the remaining shares vesting in equal monthly installments thereafter through August 31, 2022.
F5 Option vested as to 25% of the shares on February 29, 2020 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2023.
F6 Option vested as to 25% of the shares on February 28, 2021 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2024.
F7 Option vests as to 25% of the shares on June 11, 2021 with the remaining shares vesting in equal monthly installments thereafter through June 11, 2024.
F8 Option vests as to 25% of the shares on February 28, 2022 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2025.

Remarks:

Exhibit 24: Power of Attorney